ResearcherParacelsus Medical UniversityNo recent work listed
Alexander Egle
Matched on ORCID iD 0000-0003-0648-4416; OpenAlex author ID A5039762705. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 5
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 3
- Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2021.09.004↗
- C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Last author DOI 10.3390/jcm8111791↗
- Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. Last author DOI 10.1371/journal.pone.0206688↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lukas Weiß · 3 shared papers, 2018–2021 · strength 0.29
- Paper Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic c… DOI 10.1016/j.pan.2021.09.004↗
- Paper C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in P… DOI 10.3390/jcm8111791↗
- Paper Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically ava… DOI 10.1371/journal.pone.0206688↗
- Konstantin Schlick · 3 shared papers, 2018–2021 · strength 0.29
- Paper Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic c… DOI 10.1016/j.pan.2021.09.004↗
- Paper C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in P… DOI 10.3390/jcm8111791↗
- Paper Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically ava… DOI 10.1371/journal.pone.0206688↗
- Richard Greil · 3 shared papers, 2018–2021 · strength 0.29
- Paper Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic c… DOI 10.1016/j.pan.2021.09.004↗
- Paper C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in P… DOI 10.3390/jcm8111791↗
- Paper Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically ava… DOI 10.1371/journal.pone.0206688↗
- Daniel Neureiter · 1 shared paper, 2021 · strength 0.11
- Martin Pichler · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.